Alerts will be sent to your verified email
Verify Email
JENBURPH
|
Jenburkt Pharma
|
Prevest Denpro
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
0.29 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
18.49 % | 23.02 % | 8.49 % |
|
5yr average Equity Multiplier
|
1.17 | 1.16 | 1.47 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.69 | 0.58 |
|
5yr Avg Net Profit Margin
|
18.1 % | 28.95 % | 10.0 % |
|
Price to Book
|
3.36 | 5.4 | 2.65 |
|
P/E
|
18.0 | 31.42 | 79.29 |
|
5yr Avg Cash Conversion Cycle
|
-32.02 Days | 57.55 Days | 13.14 Days |
|
Inventory Days
|
24.72 Days | 26.01 Days | 66.66 Days |
|
Days Receivable
|
48.38 Days | 50.74 Days | 122.66 Days |
|
Days Payable
|
82.6 Days | 75.73 Days | 257.34 Days |
|
5yr Average Interest Coverage Ratio
|
87.2 | 75.33 | 10.36 |
|
5yr Avg ROCE
|
24.44 % | 30.18 % | 12.12 % |
|
5yr Avg Operating Profit Margin
|
22.46 % | 36.73 % | 16.84 % |
|
5 yr average Debt to Equity
|
0.02 | 0.02 | 0.14 |
|
5yr CAGR Net Profit
|
14.21 % | 17.49 % | -6.51 % |
|
5yr Average Return on Assets
|
15.8 % | 19.63 % | 5.75 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.68 % | 73.6 % | 43.16 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.95 % | 0.0 | -0.44 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Jenburkt Pharma
|
Prevest Denpro
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|